286 related articles for article (PubMed ID: 17105796)
1. PSA screening among elderly men with limited life expectancies.
Walter LC; Bertenthal D; Lindquist K; Konety BR
JAMA; 2006 Nov; 296(19):2336-42. PubMed ID: 17105796
[TBL] [Abstract][Full Text] [Related]
2. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
[TBL] [Abstract][Full Text] [Related]
3. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
4. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
5. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.
So C; Kirby KA; Mehta K; Hoffman RM; Powell AA; Freedland SJ; Sirovich B; Yano EM; Walter LC
J Gen Intern Med; 2012 Jun; 27(6):653-60. PubMed ID: 22180196
[TBL] [Abstract][Full Text] [Related]
6. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
9. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
10. Impact of age and comorbidity on colorectal cancer screening among older veterans.
Walter LC; Lindquist K; Nugent S; Schult T; Lee SJ; Casadei MA; Partin MR
Ann Intern Med; 2009 Apr; 150(7):465-73. PubMed ID: 19349631
[TBL] [Abstract][Full Text] [Related]
11. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
Drazer MW; Huo D; Schonberg MA; Razmaria A; Eggener SE
J Clin Oncol; 2011 May; 29(13):1736-43. PubMed ID: 21444863
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies.
Cho H; Klabunde CN; Yabroff KR; Wang Z; Meekins A; Lansdorp-Vogelaar I; Mariotto AB
Ann Intern Med; 2013 Nov; 159(10):667-76. PubMed ID: 24247672
[TBL] [Abstract][Full Text] [Related]
13. Predictors of prostate cancer screening among health fair participants.
Chiu BC; Anderson JR; Corbin D
Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
Hoffman KE; Nguyen PL; Ng AK; D'Amico AV
J Urol; 2010 May; 183(5):1798-802. PubMed ID: 20299039
[TBL] [Abstract][Full Text] [Related]
15. Cancer screening rates in individuals with different life expectancies.
Royce TJ; Hendrix LH; Stokes WA; Allen IM; Chen RC
JAMA Intern Med; 2014 Oct; 174(10):1558-65. PubMed ID: 25133746
[TBL] [Abstract][Full Text] [Related]
16. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
18. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
[TBL] [Abstract][Full Text] [Related]
20. Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012.
Wallner LP; Hsu JW; Loo RK; Palmer-Toy DE; Schottinger JE; Jacobsen SJ
Urology; 2015 Sep; 86(3):498-505. PubMed ID: 26123517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
